Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01158456 · ClinicalTrials.gov registry record
Metabolism of NNK Among African Americans
A clinical trial of Lung Cancer, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- 161
- Enrollment target
- 1
- Study location
NCT01158456: Completed study of Lung Cancer, sponsored by Masonic Cancer Center, University of Minnesota.
NCT01158456 is a study of Lung Cancer that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 161 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01158456, a study of Lung Cancer, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- 161 participants
- Enrollment target
- 1
- Study location
Study Summary
Metabolism and DNA adduct formation are critical in cancer induction by NNK. The investigators goal is to understand whether the observed ethnic/racial differences in lung cancer incidence are due to variations in NNK metabolism. The investigators overall hypothesis is that cancer susceptibility relates to carcinogen dose and to the balance between carcinogen metabolic activation and detoxification. The investigators propose to test this hypothesis via investigation of potential differences in NNK metabolic activation and detoxification in African American and European American smokers.
Primary Outcome
We will recruit smokers to smoke specially prepared cigarettes containing \[pyridine-D4\]NNK, and measure deuterium-labeled NNK metabolites in the urine of these subjects. The rationale for the use of deuterium-labeled NNK is that we need to specifically identify NNK-derived metabolites, because these biomarkers are also formed as a result of nicotine metabolism. Our overall hypothesis is that the relative contribution of the biomarkers of NNK metabolic activation to the total amount of NNK meta
Conditions Studied
Study Locations (1)
Minnesota
- Tobacco Research Programs University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2010-12 |
| Est. Completion | 2017-11 |
What the finished NCT01158456 record still lists
NCT01158456 is an observational study that tracks outcomes without assigning an intervention. The registered 161 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT01158456 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT01158456 about?
NCT01158456 is a clinical study titled "Metabolism of NNK Among African Americans". Metabolism and DNA adduct formation are critical in cancer induction by NNK. The investigators goal is to understand whether the observed ethnic/racial differences in lung cancer incidence are due to variations in NNK metabolism. The investigators overall hypothesis is that cancer susceptibility rel...
What is the current status of trial NCT01158456?
This trial is currently completed. The enrollment target is 161 participants. The study started on 2010-12. Estimated completion is 2017-11.
What conditions does trial NCT01158456 study?
This clinical trial studies the following conditions: Lung Cancer.
Who is sponsoring clinical trial NCT01158456?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01158456 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01158456's enrollment target sits among peer trials
161 142nd of 409 higher than 268 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06391034 · 161 participants · Phase 2
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
- NCT06546670 · 161 participants · Phase 1
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- NCT06616766 · 161 participants · Phase 1
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- NCT06752356 · 161 participants · Phase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia